|1.||Bipolar Disorder (Mania)
|2.||Anxiety Disorders (Anxiety Disorder)
|5.||Sleep Initiation and Maintenance Disorders (Insomnia)
|1.||Fava, Maurizio: 184 articles (12/2015 - 03/2002)|
|2.||Papakostas, George I: 92 articles (12/2015 - 07/2002)|
|3.||Thase, Michael E: 86 articles (12/2015 - 01/2002)|
|4.||Trivedi, Madhukar H: 74 articles (09/2015 - 01/2002)|
|5.||Nierenberg, Andrew A: 66 articles (01/2015 - 03/2002)|
|6.||Rush, A John: 62 articles (08/2015 - 01/2002)|
|7.||Mischoulon, David: 52 articles (10/2015 - 03/2002)|
|8.||Pae, Chi-Un: 49 articles (08/2015 - 02/2003)|
|9.||Alpert, Jonathan E: 47 articles (10/2015 - 03/2002)|
|10.||Kennedy, Sidney H: 42 articles (11/2015 - 01/2003)|
|1.||Antidepressive Agents (Antidepressants)IBA
03/17/2010 - "Most of the available treatment guidelines for major depressive disorders recommend the continuous use of antidepressants for 4 to 8 weeks based on the idea of a delayed onset of response to these drugs. "
12/01/2009 - "Treatment with the newer generation antidepressants is considered generally effective for most patients with major depressive disorder when taken in accordance with treatment guidelines. "
02/01/2015 - "The prevalence of major depressive disorder and the limited efficacy of conventional drug treatments provide significant impetus to develop novel and more rapidly acting antidepressants for individuals with treatment resistant forms of depression. "
01/01/2007 - "Over the past few years, a number of studies have emerged suggesting that the treatment of major depressive disorder (MDD) with antidepressants which enhance both noradrenergic as well as serotonergic neurotransmission may result in higher response or remission rates than treatment with antidepressants which selectively enhance serotonergic neurotransmission. "
10/15/2003 - "Maintenance treatment to prevent recurrences is recommended for chronic forms of major depressive disorder (MDD), but few studies have examined maintenance efficacy of antidepressants with chronic MDD. "
|2.||Citalopram (Escitalopram)FDA Link
07/01/2014 - "We investigated which factors can best predict relapse in older patients with major depressive disorder (MDD) who have achieved remission with escitalopram. "
01/01/2013 - "The results indicate that escitalopram is the most cost-effective pharmacologic treatment strategy for both regional health services compared with all SSRIs and all SNRIs used in the first-line treatment of major depressive disorder."
01/01/2007 - "Our aim in this study was to investigate the efficacy of escitalopram, a proven antidepressant, on symptoms of anxiety in patients with major depressive disorder (MDD). "
01/01/2003 - "Escitalopram 10 or 20 mg/day produced significantly greater improvements in standard measurements of antidepressant effect (Montgomery-Asberg Depression Rating Scale [MADRS], Clinical Global Impressions Improvement and Severity scales [CGI-I and CGI-S] and Hamilton Rating Scale for Depression [HAM-D]) in patients with major depressive disorder (MDD) than placebo in several 8-week, placebo-controlled, randomised, double-blind, multicentre studies. "
05/01/2009 - "This review adds to the growing body of evidence regarding differences in the dynamics of SERT occupancy, that is, molecular mechanisms underlying the often-observed superior clinical efficacy of escitalopram compared with citalopram in major depressive disorder."
|3.||duloxetine (Cymbalta)FDA Link
11/01/2007 - "Duloxetine demonstrated superior efficacy in the treatment of major depressive disorder, when compared with placebo, regardless of the baseline severity of depressive symptoms, although effect sizes were largest in the most severely depressed patients."
01/01/2011 - "Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: a meta-analysis of 11 double-blind, placebo-controlled clinical trials."
01/01/2011 - "To review efficacy of duloxetine for physical symptoms and depressive illness in patients with at least mild to moderate major depressive disorder (MDD; DSM-IV) and clinically significant painful physical symptoms at baseline. "
08/01/2007 - "This was a post hoc analysis to determine whether baseline severity of depression influenced the efficacy of duloxetine in treating major depressive disorder (MDD) and to better characterise the symptom response profile for duloxetine in patients with mild, moderate or more severe depression. "
01/01/2007 - "In placebo-controlled clinical trials, duloxetine has been shown to be effective and well-tolerated in patients with major depressive disorder (MDD). "
|4.||Serotonin (5 Hydroxytryptamine)IBA
09/01/2008 - "Monotherapy with a selective serotonin reuptake inhibitor (SSRI) is the most common initial treatment for major depressive disorder (MDD), but this monotherapy leads to remission in fewer than a third of patients. "
11/01/2011 - "Short allele (SS) variation decreases the transcriptional efficacy of serotonin, causing psychiatric disorders, major depressive disorder (MDD) and major depression in response to stressful life events. "
07/01/2013 - "The purpose of this study is to examine whether the reversal of compromised regional cerebral blood flow (rCBF) in older patients with major depressive disorder (MDD) is dependent on specific parameters of selective serotonin reuptake inhibitor (SSRI) treatment and to examine the efficacy of such treatment. "
01/01/2011 - "In this study, we used the Electro Interstitial Scan (EIS) to perform bioimpedance measurements to follow up the efficacy of selective serotonin reuptake inhibitor (SSRI) treatment in subjects diagnosed to have major depressive disorder. "
05/01/2008 - "Findings from the National Institute of Mental Health's Sequenced Treatment Alternatives to Relieve Depression trial indicate that approximately 50% of patients with major depressive disorder do not experience a treatment response after adequate first-line treatment with a selective serotonin reuptake inhibitor (SSRI). "
|5.||venlafaxine (Effexor)FDA LinkGeneric
09/01/2010 - "The data from this study indicate that venlafaxine XR is an efficient and safe therapeutic option for patients with major depressive disorder, with the additional effect of reducing associated painful physical symptoms."
04/01/2008 - "The present study indicates that maintenance treatment for 2 years with venlafaxine is cost-effective in patients with recurrent major depressive disorder."
07/01/2002 - "Venlafaxine IR/venlafaxine XR may be effective in outpatients with major depressive disorder who do not respond or have an unsustained response to SSRIs. "
06/21/2000 - "Venlafaxine extended-release (XR) capsules have been shown to be effective in short-term treatment of patients with GAD without major depressive disorder (MDD), but long-term data are needed to establish whether this agent confers persistent benefits. "
06/01/1996 - "The results from this analysis indicate that long-term treatment with venlafaxine in patients with major depressive disorder is effective in maintaining the initial response compared with placebo and suggest that venlafaxine will be effective in the prevention of relapse."
|6.||Fluoxetine (Prozac)FDA LinkGeneric
04/01/2005 - "Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder."
10/01/1986 - "A 6-week double-blind trial of fluoxetine treatment of unipolar major depressive disorder in 49 patients was evaluated in terms of improvement in the Hamilton Depression Rating Scale (HDRS) and Clinical Global Improvement (CGI) scores. "
04/01/2001 - "The results of that double-blind, placebo-controlled study suggest that fluoxetine was effective in decreasing but not eliminating both the depressive symptoms (including suicidal ideations) and the level of alcohol consumption among a study group of subjects with comorbid major depressive disorder and alcohol dependence, many of whom displayed suicidal ideations. "
08/01/1997 - "Fluoxetine is effective in reducing the depressive symptoms and the alcohol consumption of patients with comorbid major depressive disorder and alcohol dependence. "
07/01/2004 - "The efficacy of fluoxetine is now well established in the treatment of major depressive disorder. "
|7.||Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
01/01/2013 - "Selective serotonin reuptake inhibitors (SSRIs) are the most used and the most cost-effective treatment for long-term major depressive disorder. "
12/01/2005 - "Although serotonin reuptake inhibitors are recommended as first-line agents for major depressive disorder, delayed onset of action is problematic, and faster effective treatment is needed. "
08/30/2002 - "Recently, it was reported that selective serotonin reuptake inhibitors were more effective in patients with major depressive disorder having the homozygous allele pair (12-copy/12-copy) of VNTR in the STin2 than in ones having other allele combinations. "
01/01/2008 - "Selective serotonin reuptake inhibitors are a modestly effective and generally safe treatment for postpubertal major depressive disorder, but their use requires collaborative decision making and a predetermined, shared monitoring plan."
02/28/2015 - "The acute efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depressive disorder (MDD) is well established; however their role in longer-term prevention of recurrence remains unconfirmed. "
|8.||Sertraline (Zoloft)FDA LinkGeneric
01/01/2002 - "Results from several well designed trials show that sertraline (50-200 mg/day) is effective in the treatment of major depressive disorder in elderly patients (> or =60 years of age). "
01/01/2002 - "Results from several well designed trials show that sertraline (50 to 200 mg/day) is effective in the treatment of major depressive disorder in elderly patients (> or =60 years of age). "
03/01/2009 - "In non-comorbid patients, sertraline is effective for the acute treatment of major depressive disorders and prevention of relapse or recurrence. "
03/01/2005 - "Sertraline is the only treatment for major depressive disorder studied in a placebo-controlled trial of patients with ACS and found to be safe and effective. "
01/01/2011 - "Placeboxetine is as safe and effective as sertraline in Indian patients with major depressive disorder."
|9.||Norepinephrine (Noradrenaline)FDA LinkGeneric
04/01/2010 - "The current study sought to test the efficacy and safety of the novel selective norepinephrine reuptake inhibitor LY2216684 compared to placebo in patients with major depressive disorder (MDD). "
06/01/2011 - "The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). "
11/01/1999 - "Plasma norepinephrine and prediction of outcome in major depressive disorder."
02/01/1983 - "Extreme elevations in plasma norepinephrine associated with decreased alpha-adrenergic responsiveness in major depressive disorder: two case reports."
07/01/1998 - "Plasma norepinephrine and 3-methoxy-4-hydroxyphenylglycol concentrations and severity of depression in combat posttraumatic stress disorder and major depressive disorder."
|10.||aripiprazole (Abilify)FDA Link
02/01/2015 - "We describe the results of an open-label study designed to assess the effectiveness and tolerability of aripiprazole addition to an antidepressant in patients with major depressive disorder with postpartum onset who had not experienced significant clinical improvement following an adequate trial of an antidepressant. "
01/01/2015 - "There is evidence to suggest that aripiprazole is beneficial in major depressive disorder and BPD with depression. "
01/01/2011 - "Aripiprazole adjunctive to antidepressant treatment can have some beneficial effects on sexual functioning in patients with major depressive disorder who respond inadequately to standard antidepressant treatment; the benefits in women were specific to sexual interest and satisfaction and were independent of the improvement in depressive symptoms. "
01/01/2010 - "Adjunctive aripiprazole is beneficial for the treatment of patients with major depressive disorder but its effects on specific symptoms have not been reported. "
12/01/2011 - "To determine whether early symptom improvement with adjunctive aripiprazole in major depressive disorder (MDD) predicts overall symptom remission. "
|1.||Drug Therapy (Chemotherapy)
10/01/1998 - "Further research is needed on the etiology of depression; the efficacy of different types of psychotherapy; the differential effects of psychotherapy, pharmacotherapy, and integrated therapies; the continuation and maintenance treatment phases; treatment for dysthymia, treatment-resistant depression, and other subtypes of major depressive disorder; and preventive strategies for high-risk children and adolescents."
06/01/2012 - "Given the limited efficacy of current pharmacotherapy for major depressive disorder (MDD) and the historical decline in antidepressant development, there is increasing clinical urgency to develop more effective treatments. "
06/01/2008 - "A randomized clinical trial was undertaken to investigate the relative efficacy of rational-emotive behavior therapy (REBT), cognitive therapy (CT), and pharmacotherapy in the treatment of 170 outpatients with nonpsychotic major depressive disorder. "
12/01/2014 - "Although many treatments for Major Depressive Disorder (MDD) exist, only half of all patients respond to initial trial of pharmacotherapy and only a third will achieve remission with that trial. "
12/01/2009 - "Results from pivotal registration trials in major depressive disorder cohere with outcomes from effectiveness studies indicating that the majority of individuals receiving single-agent pharmacotherapy fail to achieve and sustain symptomatic remission. "
|2.||Deep Brain Stimulation
05/01/2014 - "Deep brain stimulation (DBS) in the subgenual cingulated gyrus (SCG) is a promising new technique that may provide sustained remission in resistant major depressive disorder (MDD). "
01/01/2011 - "To present the technique of deep brain stimulation (DBS) and to evaluate the studies conducted on DBS in the treatment of therapy-refractory major depressive disorder (MDD). "
12/01/2014 - "Deep brain stimulation is currently an experimental treatment for major depressive disorder. "
01/01/2013 - "This review aimed to investigate the therapeutic potential of Deep Brain Stimulation (DBS) for treating resistant Major Depressive Disorder (MDD). "
01/01/2013 - "The nucleus accumbens: a target for deep brain stimulation in resistant major depressive disorder."
|3.||Phototherapy (Light Therapy)
09/01/2012 - "The objective of this study was to investigate whether a new chronotherapeutic intervention combining wake therapy with bright light therapy and sleep time stabilization could induce a rapid and sustained augmentation of response and remission in major depressive disorder. "
04/01/2002 - "Bright light therapy can be effective in the treatment of non-seasonal major depressive disorder."
05/01/2015 - "Phototherapy, ie, bright light therapy, is an effective and safe treatment of major depressive disorder (MDD). "
09/01/2012 - "75 adult patients with DSM-IV major depressive disorder, recruited from psychiatric wards, psychiatric specialist practices, or general medical practices between September 2005 and August 2008, were randomly assigned to a 9-week chronotherapeutic intervention using wake therapy, bright light therapy, and sleep time stabilization (n = 37) or a 9-week intervention using daily exercise (n = 38). "
05/01/2012 - "Optimized light therapy for non-seasonal major depressive disorder: effects of timing and season."
01/01/2012 - "At 12 months after treatment, the mean HAM-D score was 6.45 ± 1.67 using a Friedman test, and in patients with partial remission of major depressive disorder, the HAM-D score significantly decreased after treatment with rTMS at 12 months (P = 0.001). "
08/30/2013 - "Only half of the geriatric patients with major depressive disorder (MDD) can reach full remission after treatment of half a year. "
06/01/2010 - "Studies comparing 1) HRV in patients with major depressive disorder and healthy control subjects and 2) the HRV of patients with major depressive disorder before and after treatment were considered for meta-analysis. "
01/01/2010 - "The study investigated 117 patients with partially or fully remitted major depressive disorder (MDD) after treatment with antidepressant medications. "
01/01/2015 - "In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement by rating scales 2 weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. "
01/01/2015 - "Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics."
10/01/2015 - "Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder."
08/01/2012 - "Converging lines of evidence suggest that the glutamatergic system may play an increasingly important role in the development of novel therapeutics for major depressive disorder (MDD), particularly agents associated with rapid antidepressant effects. "
01/01/2010 - "Evolving refractory major depressive disorder diagnostic and treatment paradigms: toward closed-loop therapeutics."
03/01/2008 - "Given the prevalence of major depressive disorder (MDD) and its significant economic and personal costs to society, families, and those with MDD, and given the frequent failure of contemporary therapeutics to treat MDD, it is imperative that nurses explore holistic approaches to managing MDD. "